NCT06794229 (EXPLORE-RCC) is a Phase 2 clinical trial of Zanzalintinib in Locally Advanced Renal Cell Carcinoma, sponsored by Qian Qin.

Who is sponsoring NCT06794229?

NCT06794229 is sponsored by Qian Qin.

What drugs are being tested in NCT06794229?

Interventions in NCT06794229: Zanzalintinib, Nivolumab.

What condition does NCT06794229 study?

NCT06794229 studies Locally Advanced Renal Cell Carcinoma.

Is NCT06794229 still recruiting?

NCT06794229 is currently recruiting now. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT06794229: EXPLORE-RCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

Recruiting now Phase 2 Last updated 3 April 2026

What this trial tests

Phase 2 trial testing Zanzalintinib in Locally Advanced Renal Cell Carcinoma in 69 participants. Currently enrolling.

Timeline

30 October 2025

Primary endpoint
6 June 2028

6 June 2029

Quick facts

Lead sponsor	Qian Qin
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	69
Start date	30 October 2025
Primary completion	6 June 2028
Estimated completion	6 June 2029
Sites	1 location across United States

Drugs / interventions tested

Zanzalintinib — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Locally Advanced Renal Cell Carcinoma — all drugs for Locally Advanced Renal Cell Carcinoma →

Sponsor

Qian Qin — full company profile →

Who can join

18 and older, any sex, with Locally Advanced Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All subjects will receive zanzalintinib 100mg orally (PO) once daily plus nivolumab standard of care dosing (i.e., 240mg IV every 2 weeks or 480mg IV every 4 weeks) for a total of 12 weeks, followed by restaging scan/evaluation for surgical operability and an adaptive approach that includes (1) surgical resection if the participant is eligible for surgery (Cohort A), (2) up to 48 weeks total (from Cycle 1 Day 1) of zanzalintinib plus nivolumab if the participant has partial response or stable disease but remains inoperable (Cohort B1), or (3) stopping protocol mandated treatment to receive standard of care systemic therapy and continue follow up per protocol if the participant has disease progression (Cohort B2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Zanzalintinib

Trials testing the same drug.

NCT07527169 — A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma · Phase 2 · not yet recruiting
NCT07470489 — Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer · Phase 2 · not yet recruiting
NCT07283731 — Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma · Phase 2 · recruiting
NCT07489495 — A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-0 · Phase 3 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting

Other recruiting trials for Locally Advanced Renal Cell Carcinoma

Currently open trials in the same condition.

NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06794229 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qian Qin
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06794229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing